Article Sidebar
Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effects of sitagliptin on blood glucose, lipids, pancreatic β cell secretory function and insulin resistance in patients with type 2 diabetes mellitus
Abstract
Purpose: To study the influence of sitagliptin on blood glucose, lipid and pancreatic β cell function in type II diabetes mellitus (T2DM) patients.
Methods: Two groups of T2DM patients (100/group) received either metformin only (control group), or metformin plus sitaglipin (study group) for 3 months. Blood lipid profiles, fasting blood glucose (FBG), indices of pancreatic function and insulin resistance were assayed using standard biochemical methods.
Results: The metformin-sitaglipin combination resulted in significant decreases in FBG, 2-h PBG, HbAlc total cholesterol (TC), triacylglycerol, and low-density lipoprotein cholesterol (LDL-C), when compared with the metformin-only treatment (p < 0.05). Although there were significant decreases in pancreatic secretion of insulin, fasting insulin, and 2 h postprandial insulin in the two groups, these parameters were significantly lower in the metformin-only treated patients than in those with combination treatment (p < 0.05).
Conclusion: Sitagliptin normalizes fasting blood glucose, lipid profiles and insulin secretion in type II diabetes mellitus (T2DM) patients.
Keywords: Type 2 diabetes mellitus, Sitagliptin, Blood glucose, Pancreatic islet function, Insulin
